VMS Vortex Metals Inc

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX
VENTURE:VPT) today announced the final closing of its previously announced
private placement of Units (the "Units") of the Corporation (the "Offering") for
aggregate gross proceeds of $816,013. Pursuant to the Offering and previously
announced closing, the Corporation raised total proceeds of $1,052,317 and
issued a total of 1,052,317 Units at a price of $1.00 per Unit. Each Unit
consists of a secured debenture promissory note (the "Debentures") with an
interest rate of 8% per annum and four share purchase warrants (the "Warrants")
of the Corporation. Each Warrant is exercisable into one common share of the
Corporation (the "Common Share") at an exercise price of $0.15 per Common Share
for a period of three years from the date of issuance. The Debentures will have
a maturity date of three years from the date of issuance and will be redeemable
at the option of the Corporation any time after one year from the date of
issuance.


In conjunction with the Offering, VentriPoint paid a cash commission of $21, 000
and issued 140,000 non-transferable warrants exercisable into Common Shares at a
price of $0.15 per Common Share. All securities issued pursuant to the Offering
are subject to a four-month hold period pursuant to applicable securities
legislation. The proceeds made available through the sale of Units will be used
to incur expenditures in preparation for and implementation of product and
service commercialization, applied to deferred wages and for working capital
purposes.


About VentriPoint Diagnostics Ltd.

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid and inexpensive manner not
currently available. Health Canada has granted licensed approval for the VMS
breakthrough diagnostic tool which is based upon technology received by
VentriPoint through its exclusive technology license with the University of
Washington. The VMS, together with its associated online service, is being
developed for a variety of heart related disease states, including congenital
heart disease and pulmonary hypertension.


To receive press release, please email chris@chfir.com and mention VentriPoint
in the Subject line.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.

Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024